CureVac and UK Government to collaborate on development of vaccines against SARS-CoV-2 variants
- Collaboration combines expertise, resources and technology from both parties to develop and manufacture variant vaccines for commercial supply and distribution in the UK and its territories
- Objective is to mitigate the effects of the current pandemic and to help manage future outbreaks by forming a rapid response unit leveraging the unique strengths of CureVac’s mRNA platform
- Under this agreement, CureVac is expected to supply 50 million doses of variant vaccines to the UK, subject to regulatory approval
CureVac N.V., a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA), today announced that it has entered a collaboration with the UK Government to develop and manufacture potential vaccine candidates against SARS-CoV-2 variants. Any resulting vaccine candidates will be manufactured and distributed in the UK and its overseas and dependent territories, subject to regulatory approval. The objective of the collaboration is to mitigate the effects of the current pandemic and help prepare against future SARS-CoV-2 outbreaks by working on multiple variant vaccines.